secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2023-02-27T23:59:59+00:00
Accession:  0001213900-23-014884
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed Pharmaceuticals adopts amended bylaws with new stockholder consent rules and indemnification limits
--------------------------------------------------------------------------------

- Board adopted Fourth Amended and Restated By-laws effective February 23, 2023.
- New rules for stockholder action by written consent, including record date and independent inspector of election.
- Limits indemnification for proceedings commenced by the person unless board-authorized.
- Reduces indemnification by amounts collected from other entity for service at another entity.
- Requires affirmative vote of majority of outstanding shares to alter, amend, or repeal bylaws.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390023014884/0001213900-23-014884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390023014884/ea174308-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-014884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer